Optimi Health Corp. announced that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specifications. Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.

The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications. The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption. After six months of accelerated data collection, Optimi confirms that its Natural Psilocybin Extract maintained its original potency level without any degradation during stability testing.

Furthermore, the Psilocybe cubensis mushrooms used in creating the extract were cultivated in-house under Good Agricultural Collection Practice (GACP) conditions. As the Company prepares to meet its Australian supply commitments with Mind Medicine Australia, Karina Lahnakoski, Optimi's Director of Quality and Commercial Strategies, assures patients and therapists of the reliability and quality of Optimi's drug candidates. Dedicated to fostering collaborations and advancing the scientific understanding of the potential therapeutic benefits of psilocybin, Optimi welcomes inquiries from principal investigators and research groups interested in learning more about the Company?s validated GMP Natural Psilocybin Extract and other drug candidates.